Ministero della Salute

Organisation

Acronym: IT-MOH
Role: Partner
Country: IT
Address: Viale Giorgio Ribotta, 5 - 00144 - Roma
Website: https://www.salute.gov.it/portale/home.html

Programme phases

Funding participation

Joint calls funded by this organisation.

Funded projects

Projects linked to this funding organisation.

HAPLO-IMMUNE

RE-VOLU-TION

Ministero della Salute

Organisation

Programme phases

Funding participation

Funded projects

Functional precision medicine platform for the treatment of pancreatic cancer

A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients

Building an ex vivo complex tumour microenvironment platform for development of combination therapies and drug resistance studies in head neck cancer

K-RAS mutations and DNA repair function in NSCLC

Biomarkers of tumor recurrence in pancreatic cancer

MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases

Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection.

Epigenomic regulation of cancer immunity by dietary intervention

A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention

Impact of Dietary Intervention on tumor immunity

Defeating Recurrence and resistance in AML: Multigenomic Approaches to analyse heterogeneity

Dual EPigenetic targeting and Immunotherapy to fight against Cancer

Sarcoma subtyping and stratification using genome-wide epigenetic profiling

Identifying EPIgenetic determinants and biomarkers of drug resistance via characterization of PROspective PERsister cells

Unveiling the Epigenetic Landscape and Therapeutic Implications of Epigenetic Modifiers in Human T-cell Leukemia Initiation and Progression

Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT

An integrated european platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure

Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance

Identification of genetic markers involved in development of metastases and second cancers in melanoma

Multiparameric Analysis of the Evolution and Progression of Low-Grade Glioma (LGG)

Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid carcinoma

Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia

Mutated neo-antigens in hepatocellular carcinoma

High resolution project on prognosis and CARE of cancer patients

New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors

Deciphering immune response against glioblastoma to find new targets

Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies

Targeting sphingolipid metabolism to improve anti-melanoma immune therapies

Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer

Evolution of resistant clones to novel target-directed drugs in colorectal tumors. - A genetic and epigenetic study of intratumoral heterogeneity dynamics

Understanding and therapeutically exploiting the immunosuppressive paracrine signalling in the tumour microenvironment of metastatic lesions

Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation.

Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy

Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas

Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids

A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence

Metabolism/Metagenomics-based strategies for sensitization to Radio- and Immuno- therapy Combinations.

Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical "proof-of-concept" to the development of phase I studies

Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients

Innovative peptide- and RNA-based strategies to modulate p53 for pancreatic cancer therapy

Predictive models of therapy response in pancreatic neuroendocrine tumors

Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance.

Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma

Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin

Profiling radioREsistant Differentiated thyroId Cancer: genes, immunity, cancer stem cells and epithelial-mesenchymal transition

Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary Cancer

Early Detection of Prostate Cancer by Liquid Biopsies

PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine

New immunotherapies targeting the key purinergic checkpoints in the tumor microenvironment

Non-invasive prognostic markers for Resected Early-STage NSCLC: role of circulatING and exosomal miRNAs and free circulating DNA

pREdiction of niVOLUmab acTION in metastatic renal cancer patients: Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy.

Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.

Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms

Standardized Profiling of Epigenetic Loci for decentralized ClAssification of Sinonasal Tumors and idEntification of therapy Response markers

TArgeting Colon Tumor Initiating Cell heterogeneity

TArgeting acute myeloid Leukemia immunosuppressive microEnvironment by combined IDO1 inhibiTion and PD-1 blockadE

Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response

Early detection of relapses in stage II-III colon cancer patients by following a personalized molecular signature from a blood test: THRuST

A TranslatiOnal Platform for de-orphaning malignant pleural MESOthelioma

Targeting Of Resistance in PEDiatric Oncology (TORPEDO)

TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform

Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice

CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer